Login

RFPs & Calls for Grant Applications

Current RFPs and Call for Grant Applications
<< First  < Prev   1   2   Next >  Last >> 
  • 23 May 2017 11:10 AM | Anonymous

    UPDATE: Grant requests are due to Regeneron no later than Thursday, June 15, 2017.   Note: Submissions will be reviewed on an ongoing first come, first served basis

    Regeneron invites retina fellowship programs to submit requests for independent medical education grants (IME) subject to the following terms:

    Retina Fellowship RFP SACME Final v2.pdf

     

  • 10 May 2017 4:46 PM | Jim Ranieri (Administrator)

    Date CGA Issued: May 9, 2017

    Clinical Area: Oncology Outcomes & Evidence

    Link to full CGA:Understanding Oncology Clinical Trial Outcomes and Comparative Assessment

    Due Date: June 21, 2017

    Specific Area of Interest: It is our intent to support continuing professional development programs (CME/CE) for managed care decision-makers, formulary decision-makers, other payor decision-makers, pharmacists/pharmacy directors, and medical oncologists/medical directors. Proposed programs should focus on increasing the understanding of one or more of the following topics, in order of priority:

    1.    Formulary Class Review & Considerations: Examining Current and Emerging Agents in the CDK 4/6 Inhibitor Class for the Treatment of HER2(-)/ER(+) Advanced or Metastatic Breast Cancer

    2.    The use of Patient Reported Outcomes (PROs) in Oncology Versus Other Therapeutic Areas and a Primer for Payers to the PRO-Common Terminology Criteria for Adverse Events Tool (PRO-CTCAE tool)

    3.    Application & Limitations of Evidenced-Based Methods for Indirect Treatment & Trials Comparisons: Value frameworks (ASCO Value Framework, NCCN Evidence Blocks, etc) and Real World Data for indirect treatment comparisons; and Network Meta-Analysis (NMA), Simulated Treatment Comparison (STC), Match Adjusted Treatment Comparison (MAIC), etc. for indirect trials comparisons

    4.    Challenges with Oncology Trial Design/Approvals & Endpoints in Value Assessment

    Questions regarding this CGA should be directed to derek.warnick@pfizer.com.


  • 09 May 2017 12:25 PM | Jim Ranieri (Administrator)

    Request for Proposal (RFP)
    Shared Management of Psoriatic Arthritis

    The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

    Date RFP Issued: May 8, 2017

    Clinical Area: Psoriatic Arthritis

    Link to full RFP: Shared Management of Psoriatic Arthritis

    LOI Due Date: June 23, 2017

    Specific Area of Interest:   Evidence indicates that many patients with Psoriatic Arthritis (PsA) remain undiagnosed, and those who have been diagnosed are not receiving optimal care. It is our intent to support projects that focus on the coordinated management and identification of patients with psoriatic arthritis (PsA) by both rheumatology and dermatology healthcare professionals. 

    Patients with Psoriatic Arthritis experience symptoms that involve both the skin and the joints, impacting their quality of life. Given the nature of the disease, patients may seek care from both dermatologists and rheumatologists, as the disease progresses through periods of flare and remission. A collaborative approach to treatment by a combined team of rheumatology and dermatology clinicians allows for a unique blend of expertise and provides the opportunity for comprehensive care for the PsA patient.

    It is expected that projects will be evidence-based and the proposed evaluation will follow generally accepted scientific principles. During review the intended outcome of the project is given careful consideration and, if appropriate based on the project goal, projects with the maximum likelihood to directly impact patient care will be given high priority.

    Refer to complete details in the Full RFP document. Questions regarding this RFP should be directed to amanda.solis@pfizer.com.

  • 09 May 2017 10:59 AM | Jim Ranieri (Administrator)

    Pfizer and Bristol-Myers Squibb (BMS) are working together on grants in support of innovative cardiovascular therapies. The goal of these grants is to improve patient care and outcomes through therapy innovation.

    PLEASE NOTE: Responses to the RFP listed below should be made through the Bristol-Myers Squibb Grants and Giving website: 

    http://www.bms.com/responsibility/grantsandgiving/support/pages/default.aspx

    Request for Proposals (RFP)
    Eliminating Barriers to Innovate Cardiovascular Therapies
    to Improve Patient Care and Outcomes

    Date RFP Issued: May 1, 2017

    Clinical Area: Cardiovascular

    Link to full RFP:  Eliminating Barriers to Innovate Cardiovascular Therapies to Improve Patient Care and Outcomes

    Due Date: June 28, 2017

    Geographic Scope: United States​

    Specific Area of Interest: Chronic disease is the leading cause of death and disability in the United States. Accessing affordable treatments is vital for all Americans. There are many factors that may limit both patient and provider ability to access the newest and most innovative therapies including restrictive formularies, step therapy, non-medical switching, cost and cumbersome administrative processes including prior authorization and tier exception processes. The strategies employed to address these barriers may include

    ·         Gaining an understanding of barriers from each stakeholder’s point of view (HCP, Patient, administrative staff, caregivers, others)

    ·         Developing best practices that can inform advocacy organizations and medical societies, including the role each could play in the evolving access landscape

    Questions regarding this RFP should be directed to nicole.peterson@bms.com.

  • 04 May 2017 5:03 PM | Jim Ranieri (Administrator)

    You are invited to submit a grant proposal to address the educational need outlined in the attached document.

    Please review and return your completed proposal via the sanofi U.S. Grant Website at https://sgrants.envisionpharma.com/vt_sgrants/ by 5p.m. EST on Wednesday, June 14, 2017.

     If a submission is not completed by this date, your proposal will not be accepted.

    When entering proposal into the website, please reference the following:

    Therapeutic Area:     Immunology

    Area of Interest:        Rheumatoid Arthritis

    RFP Name:                  Glbl RA RFP – Gnrl – 6/17

    “Please note that an applicant may be ineligible to receive a grant in response to this RFP if the applicant has performed any services under contract with

    sanofi U.S. during the last 12 months in connection with:

    • A consultant meeting; or
    • An advisory board meeting

    in the same therapeutic area as this request for proposal (“RFP”).

    If the applicant has performed such services, please forward a copy of the contract immediately, prior to responding to the RFP, so that we can determine your

    eligibility.  If not, please acknowledge this in your application writing.”

    Please note that you must select the type of activity that you are proposing, i.e., Live, Enduring or Live and Enduring and answer the question, “Are you responding to an RFP” and Please select “Glbl RA RFP – Gnrl – 6/17 “ from the RFP

    dropdown panel within the grant portal upon submitting your applicant for this RFP.

    Submission instructions are available on the website. If you have a content question, please contact Malika Wicks at Malika.Wicks@sanofi.com.


  • 04 May 2017 5:01 PM | Jim Ranieri (Administrator)

    You are invited to submit a grant proposal to address the educational need outlined in the attached document.

    Please review and return your completed proposal via the sanofi U.S. Grant Website at https://sgrants.envisionpharma.com/vt_sgrants/ by 5p.m. EST on Wednesday, June 14, 2017.

     If a submission is not completed by this date, your proposal will not be accepted.

    When entering proposal into the website, please reference the following:

    Therapeutic Area:     Immunology

    Area of Interest:        Rhuematoid Arthritis

    RFP Name:                  Glbl RA RFP-WAD – 6.17

    “Please note that an applicant may be ineligible to receive a grant in response to this RFP if the applicant has performed any services under contract with

    sanofi U.S. during the last 12 months in connection with:

    • A consultant meeting; or
    • An advisory board meeting

    in the same therapeutic area as this request for proposal (“RFP”).

    If the applicant has performed such services, please forward a copy of the contract immediately, prior to responding to the RFP, so that we can determine your

    eligibility.  If not, please acknowledge this in your application writing.”

    Please note that you must select the type of activity that you are proposing, i.e., Live, Enduring or Live and Enduring and answer the question, “Are you responding to an RFP” and Please select “Glbl RA RFP-WAD – 6.17“ from the RFP

    dropdown panel within the grant portal upon submitting your applicant for this RFP.

    Submission instructions are available on the website. If you have a content question, please contact Malika Wicks at Malika.Wicks@sanofi.com.


  • 02 May 2017 12:52 PM | Anonymous

     

    Call for Grant Applications (CGA)

    General Practitioner Educational Needs Assessment

    in Asia Pacific (APAC)

     

     

    Date CGA Issued: April 27, 2017

    Clinical Area: Asia Pacific Needs Assessment

    Geographic Scope: Thailand, Philippines, Malaysia, Pakistan, Indonesia, Vietnam, India, South Korea, Singapore

    Link to full CGA: General Practitioner Educational Needs Assessment in Asia Pacific

    Due Date: June 9, 2017

     

    Specific Area of Interest: It is our intent to provide an independent grant to an organization or organizations who will conduct a thorough educational needs assessment for general practitioners (GPs) practicing in the APAC region.

     Questions regarding this CGA should be directed to angelo.carter@pfizer.com

     

     

  • 24 Apr 2017 11:34 AM | Anonymous

     

    Release Date: April 14, 2017

    A Focus on the Issues: Historically, veterinary pathologists have played a key role as scientific investigators in addition to their contributions as diagnostic pathologists, teachers, and research collaborators, which is why research is considered to be a crucial element of best practices in pathology training.1-4 Nevertheless, data obtained from the American College of Veterinary Pathologists (ACVP) suggest that for several decades now, there has been a slowing or decrease of the number of veterinary pathologists and in particular veterinary pathologists with research training despite the calls for increase in the numbers of those veterinary scientists.

    Please read the attachment for complete Notification:

         CGN_gRAF Vet Path_2Qtr2017.pdf

     

  • 21 Apr 2017 1:29 PM | Anonymous

    Release Date: April 14, 2017

    A Focus on the Issues: In recent years, several issues have emerged that are critical to defining future directions for the scientific projects that enable systems to use translational or implementation research to improve patient care. There exists a growing body of research that highlights the ineffectiveness of a ‘one size fits all’ approach to treatment. Research cited in the international weekly journal of science, Nature1, revealed the limited reach of therapeutics, noting that of the ten most popular drugs prescribed in the U.S., some ultimately reach as few as one in 25 eligible patients.1 Today’s healthcare practitioners and their research counterparts remain accountable, but they are continuously challenged to understand myriad factors that influence a person’s care: medical records, genetic profile, environmental & social background, and other elements. As a result, a majority of healthcare plans continue to be made with insufficient data, hindering a healthcare system’s ability to address qualified gaps. Furthermore, it takes, on average, seventeen years for clinical evidence to fully integrate into practice; additionally, 20% of core information guiding clinical decisions changes within one year.

         Please see attachment for complete Grant Notification:

               CGN_gRAF Precision Care_2Qtr2017.pdf

              

     

  • 20 Apr 2017 2:04 PM | Anonymous

    Release Date: April 14, 2017

    A Focus on the Issues: Informed clinicians are essential to promoting positive patient outcomes. On average 20% of the core information guiding clinical decisions typically change within one year because of the appropriate tide of consistently emerging data.1 Healthcare practices and their clinicians are challenged with preparing to efficiently absorb new information that could impact their care decisions with patients. Clinicians often seek a more efficient information infrastructure to better connect them to data exposure, and evaluating emerging evidence-based information for their patients and families. With emerging data in therapeutic areas offering preference sensitive treatments, shared decision making (SDM) and patient engagement is a valuable method that can help improve satisfaction and ultimately improve2 patient outcomes, and lower costs of care.3-5 Unfortunately, while SDM is supported in the reformed healthcare marketplace focused on developing higher quality care, it is poorly adopted by clinicians today, and the care patients receive may not necessarily align to their preferences.

                        Please see attachment for complete Notification:

                                CGN IME Emerging Areas_2Qtr2017.pdf

     

     

<< First  < Prev   1   2   Next >  Last >> 
Powered by Wild Apricot Membership Software